Evidence map›Paper›PMID 38594390›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

Financial difficulties experienced by patients with gastrointestinal stromal tumours (GIST) in the Netherlands: data from a cross-sectional multicentre study.

Deborah van de Wal, Dide den Hollander, Ingrid M E Desar, Hans Gelderblom, Astrid W Oosten, Anna K L Reyners, Neeltje Steeghs, Olga Husson, Winette T A van der Graaf

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 3 pooled it
1.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 syntheses or guidelines pooled it, 1 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Deborah van de WalDepartment of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-3898-6093
Dide den HollanderDepartment of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0003-2077-2633
Ingrid M E DesarDepartment of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0003-0945-8299
Hans GelderblomDepartment of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands.ORCID http://orcid.org/0000-0001-9270-8636
Astrid W OostenDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0003-2850-0501
Anna K L ReynersDepartment of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0003-1678-7816
Neeltje SteeghsDepartment of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0003-2989-2279
Olga HussonDepartment of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-1387-8686
Winette T A van der GraafDepartment of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. w.t.a.vandergraaf@erasmusmc.nl.ORCID http://orcid.org/0000-0001-7549-3338
The Netherlands Cancer Institute · NLErasmus MC Cancer Institute · NLRadboud University Nijmegen · NLLeiden University Medical Center · NLUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aims to (1) explore the prevalence of patient-reported financial difficulties among GIST patients, differentiating between those currently undergoing tyrosine kinase inhibitor (TKI) treatment and those who are not; (2) investigate associations between financial difficulties and sociodemographic and clinical characteristics, work, cancer-related concerns, anxiety and depression and (3) study the impact of financial difficulties on health-related quality of life.

methodsA cross-sectional study was conducted among Dutch GIST patients diagnosed between 2008 and 2018, who were invited to complete a one-time survey between September 2020 and June 2021. Patients completed nine items of the EORTC item bank regarding financial difficulties, seven work-related questions, the Hospital Anxiety and Depression Scale, Cancer Worry Scale and EORTC QLQ-C30.

resultsIn total, 328 GIST patients participated (response rate 63.0%), of which 110 (33.8%) were on TKI treatment. Patients currently treated with TKIs reported significantly more financial difficulties compared to patients not on TKIs (17.3% vs 8.7%, p = 0.03). The odds of experiencing financial difficulties was 18.9 (95% CI 1.7-214.7, p = 0.02) times higher in patients who were less able to work due to their GIST diagnosis. Patients who experienced financial difficulties had significantly lower global quality of life and functioning, and more frequently reported psychological symptoms as compared to patients who did not report financial difficulties.

conclusionEven in a country where the costs of TKIs and follow-up care are covered by health insurance, financial difficulties can be present in GIST patients, especially in patients on TKI treatment, and may negatively influence the quality of life.

Indexed as

Gastrointestinal NeoplasmsGastrointestinal Stromal TumorsCross-Sectional StudiesHumansNetherlandsProtein Kinase InhibitorsQuality of LifeProtein Kinase InhibitorsFinancial difficultiesFinancial toxicityGastrointestinal stromal tumourPatient-reported outcomeQuality of lifeTyrosine kinase inhibitors

Identifiers

PMID38594390
PMCPMC11004045
OpenAlexW4394687231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.